Paper4348752
The use of drugs in combination for the treatment of cancer: rationale and results.
DeVita VT and 1 other. N Engl J Med, 1973. Cited by 192 papers, by iCite.
Cite this record
ConductScience Library. The use of drugs in combination for the treatment of cancer: rationale and results. Papers, record 4348752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4348752
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Breast Neoplasms | |
| Child | |
| Dose-Response Relationship, Drug | |
| Drug Resistance | |
| Drug Synergism | |
| Female | |
| Gastrointestinal Neoplasms | |
| Hodgkin Disease | |
| Humans | |
| Leukemia L1210 | |
| Leukemia, Lymphoid | |
| Leukemia, Myeloid, Acute | |
| Lymphoma | |
| Male | |
| Models, Biological | |
| Neuroblastoma | |
| Remission, Spontaneous | |
| Testicular Neoplasms | |
| Time Factors | |
| Wilms Tumor |
Source PubMed
Cited by39
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 192 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42054999 | Rethinking the role of synergy calculations in the next century of drug combination discovery. | Med | 2026 | https://conductscience.org/library/papers/42054999 | PubMed |
| 40088336 | Predicting Synergistic Drug Combinations Based on Fusion of Cell and Drug Molecular Structures. | Interdiscip Sci | 2025 | https://conductscience.org/library/papers/40088336 | PubMed |
| 37974028 | Additivity predicts the efficacy of most approved combination therapies for advanced cancer. | Nat Cancer | 2023 | https://conductscience.org/library/papers/37974028 | PubMed |
| 37121274 | High-throughput approaches to uncover synergistic drug combinations in leukemia. | SLAS Discov | 2023 | https://conductscience.org/library/papers/37121274 | PubMed |
| 36685168 | Combination Chemotherapy of Multidrug-resistant Early-stage Colon Cancer: Determining Optimal Dose Schedules by High-performance Computer Simulation. | Cancer Res Commun | 2023 | https://conductscience.org/library/papers/36685168 | PubMed |
| 34983746 | Independent Drug Action in Combination Therapy: Implications for Precision Oncology. | Cancer Discov | 2022 | https://conductscience.org/library/papers/34983746 | PubMed |
| 34670583 | Prediction of synergistic drug combinations using PCA-initialized deep learning. | BioData Min | 2021 | https://conductscience.org/library/papers/34670583 | PubMed |
| 32774773 | cGAS-STING pathway in oncogenesis and cancer therapeutics. | Oncotarget | 2020 | https://conductscience.org/library/papers/32774773 | PubMed |
| 31032838 | CANCROX: a cross-species cancer therapy database. | Database (Oxford) | 2019 | https://conductscience.org/library/papers/31032838 | PubMed |
| 30203598 | In Vivo Anticancer Activity of a Nontoxic Inert Phenolato Titanium Complex: High Efficacy on Solid Tumors Alone and Combined with Platinum Drugs. | ChemMedChem | 2018 | https://conductscience.org/library/papers/30203598 | PubMed |
| 29245008 | On the Design of Combination Cancer Therapy. | Cell | 2017 | https://conductscience.org/library/papers/29245008 | PubMed |
| 28446463 | The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. | Cancer Res | 2017 | https://conductscience.org/library/papers/28446463 | PubMed |
| 28376154 | Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. | J Natl Cancer Inst | 2017 | https://conductscience.org/library/papers/28376154 | PubMed |
| 27641330 | Translational research in neuroendocrine tumors: pitfalls and opportunities. | Oncogene | 2017 | https://conductscience.org/library/papers/27641330 | PubMed |
| 26088171 | Preclinical optimization of a broad-spectrum anti-bladder cancer tri-drug regimen via the Feedback System Control (FSC) platform. | Sci Rep | 2015 | https://conductscience.org/library/papers/26088171 | PubMed |
| 25493378 | Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer. | Braz J Med Biol Res | 2015 | https://conductscience.org/library/papers/25493378 | PubMed |
| 23998076 | Tackling the problems of tumour chemotherapy by optimal drug scheduling. | J Clin Diagn Res | 2013 | https://conductscience.org/library/papers/23998076 | PubMed |
| 23805101 | Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. | Front Pharmacol | 2013 | https://conductscience.org/library/papers/23805101 | PubMed |
| 23164555 | Understanding resistance to combination chemotherapy. | Drug Resist Updat | 2012 | https://conductscience.org/library/papers/23164555 | PubMed |
| 22733553 | Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. | EMBO Mol Med | 2012 | https://conductscience.org/library/papers/22733553 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4348752
GET https://conductscience.org/api/papers/v1/4348752/cited_by?page=2